AMERICAN VANGUARD CORP

Listed Company

AVDCIK 0000005981NYSEAcceleratedAgricultural ChemicalsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$515.11M

Net Income

$-49.88M

Total Assets

$596.54M

Equity

$192.40M

Shares Out

28.54M

Op. Cash Flow

$-21.19M

Business

AMERICAN VANGUARD CORP is a holding company that operates through its principal subsidiaries to develop, manufacture and market chemical, biological and biorational solutions for agricultural, commercial and consumer uses. It synthesizes and formulates technical-grade active ingredients and end-use products — including insecticides, fungicides, herbicides, soil health and plant nutrition products, molluscicides, growth regulators, soil fumigants, microbial biorationals and closed delivery systems — and provides custom manufacturing, licensing and distribution services. The company reports a single operating segment and conducts activities through domestic and international subsidiaries such as AMVAC, GemChem, Envance, TyraTech, OHP, AMVAC BV, AgriCenter and Agrinos. Products are sold in the U.S. primarily through national distributors, buying groups and co‑operatives and internationally via sales offices, wholly owned distributors and local agents across Central America, Mexico, Brazil, Australia, New Zealand, India and other territories.

Summary from filing dated 2025-05-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	515	547	579	610	558
Cost of sales	−368	−427	−400	−417	−387
Gross profit	148	120	179	192	171
Selling, general and administrative	−111	−120	−117	−120	−111
Research, product development and regulatory	−23	−33	−38	−32	−29
Product liability claims	−10	0	0	—	—
Transformation	−7	−20	−957,000	0	—
Asset impairment	−25	−50	0	0	—
Gain from sale of assets	249,000	1	0	0	—
Operating (loss) income	−28	−102	23	41	31
Change in fair value of equity investments, net	−437,000	−2	−359,000	−732,000	−790,000
Interest and other interest expenses, net	−18	−17	−13	−4	−4
(Loss) income before provision for income taxes	−47	−120	10	36	—
Provision for income taxes	−3	−6	−3	−9	−8
Net (loss) income	−50	−126	8	27	—
(Losses) earnings per common share-basic	−1.75	−4.5	0.27	0.94	0.62
(Losses) earnings per common share-assuming dilution	−1.75	−4.5	0.26	0.92	0.61
Weighted average shares outstandingbasic	28	28	28	29	30
Weighted average shares outstandingassuming dilution	28	28	29	30	30

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-03-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash	12	—	13	11	20
Trade, net of allowance for credit losses of $11,733 and $9,190 respectively	161	—	170	183	156
Other	7	—	5	8	10
Total receivables, net	168	—	174	191	166
Inventories	176	—	179	220	184
Prepaid expenses and other assets	10	—	8	6	16
Income taxes receivable	5	—	5	4	2
Total current assets	371	—	379	432	389
Property, plant and equipment, net	53	—	58	75	71
Operating lease right-of-use assets, net	17	—	20	22	24
Intangible assets, net	139	—	150	173	185
Goodwill	0	20	20	51	47
Deferred income tax assets	3	—	1	3	141,000
Other assets	15	—	8	12	11
Total assets	597	—	637	768	726
Accounts payable	88	—	69	69	69
Customer prepayments	33	—	53	66	111
Accrued program costs	52	—	69	68	61
Accrued expenses and other payables	28	—	32	16	21
Operating lease liabilities, current	6	—	6	6	5
Income taxes payable	3	—	3	6	0
Total current liabilities	209	—	232	230	267
Long-term debt	174	—	147	139	51
Operating lease liabilities, long-term	12	—	14	17	19
Deferred income tax liabilities	8	—	8	8	15
Other liabilities	923,000	—	2	3	4
Total liabilities	404	—	404	398	356
Commitments and contingent liabilities (Notes 5 and 10)	—	—	—	—	—
Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued	0	—	0	0	0
Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,923,562 shares in 2025 and 34,794,548 shares in 2024	3	—	3	3	3
Additional paid-in capital	117	—	115	111	106
Accumulated other comprehensive loss	−12	—	−19	−6	−12
Retained earnings	155	—	205	333	329
Total stockholders' equity including treasury stock	264	—	304	441	426
Less treasury stock at cost, 5,915,182 shares in 2025 and 5,915,182 in 2024	−71	—	−71	−71	−56
Total stockholders equity	192	—	233	370	370
Total liabilities and stockholders equity	597	—	637	768	726

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization of property, plant and equipment and intangible assets	19	22	22	22	22
Amortization of other long-term assets	21,000	226,000	2	4	4
Amortization of deferred loan fees	2	536,000	254,000	289,000	359,000
Gain on disposal of property, plant and equipment	−75,000	−1	0	268,000	194,000
Impairment of assets	25	50	0	0	—
Provision for estimated credit losses	2	2	2	1	649,000
Stock-based compensation	2	4	6	6	7
Deferred income taxes	−1	1	−10	−5	−2
Changes in liabilities for uncertain tax positions or unrecognized tax benefits	−201,000	−2	−508,000	−1	−2
Lease obligations and non-cash lease expense, net	−147,000	−37,000	256,000	—	—
Unrealized foreign currency transaction (gains) losses	−193,000	804,000	−581,000	−29,000	−225,000
Decrease (increase) in receivables	8	7	−20	−6	−24
Decrease (increase) in inventories	6	35	−27	−29	9
Decrease (increase) in income tax receivable/payable	−9,000	−4	4	−5	6
(Increase) decrease in prepaid expenses and other assets	−9	−687,000	1	−3	−5
Increase (decrease) in accounts payable	15	4	−2	2	9
Decrease in customer prepayments	−20	−13	−45	48	19
(Decrease) increase in accrued program costs	−17	2	7	−2	18
(Decrease) increase in accrued expenses and other payables	−4	17	−5	90,000	4
Net cash (used in) provided by operating activities	−21	4	−59	57	86
Capital expenditures	−4	−7	−12	−13	−10
Proceeds from disposal of property, plant and equipment	477,000	1	242,000	84,000	0
Acquisitions of business and product line, net of cash acquired	0	0	−5	0	−10
Intangible assets	−165,000	−409,000	−186,000	−1	−524,000
Net cash used in investing activities	−4	−7	−17	−14	−20
Payments under line of credit agreement	−223	−294	−173	−254	—
Borrowings under line of credit agreement	250	303	259	253	—
Payment of deferred loan fees	−3	−850,000	0	0	—
Net receipt from the issuance of common stock under ESPP	629,000	901,000	981,000	837,000	743,000
Net (payment) receipt from the exercise of stock options	−205,000	0	46,000	827,000	172,000
Payment from common stock purchased for tax withholding	0	−1	−2	−2	−3
Repurchase of common stock	0	0	−16	−34	−5
Payment of cash dividends	0	−3	−3	−3	−2
Net cash provided by financing activities	24	5	67	−38	−66
Net increase (decrease) in cash	−1	2	−9	4	448,000
Effect of exchange rate changes on cash	1	−742,000	116,000	−332,000	−86,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro